Results 91 to 100 of about 76,424 (294)
Acta Psychiatrica Scandinavica, EarlyView.ABSTRACT Background Schizophrenia is characterized by positive, negative, and cognitive symptoms. Current pharmacological treatments often fail to address cognitive deficits. In this review of clinical trials, we aim to identify studies that explore neurobiological (non‐psychological) strategies to address Cognitive Impairment Associated with ...
Bahareh Peyrovian +3 more
wiley +1 more source
BMC Psychiatry, 2020 Background Clozapine is an atypical antipsychotic proven to be superior in the treatment of treatment-resistant schizophrenia. Myocarditis is a rare, but well-known complication of treatment with clozapine.
M. Z. van der Horst +2 more
doaj +1 more source
Psychiatric manifestations of multiple sclerosis and acute disseminated encephalomyelitis [PDF]
, 2006 It is unusual for acute disseminated encephalomyelitis and multiple sclerosis to present as purely psychiatric disorders. We report five patients with such demyelinating diseases and symptoms of psychosis, depression or anxiety.
Brinar, Marko +3 more
core +1 more source
Australian Dental Journal, EarlyView.ABSTRACT Objectives To assess the oral health status of patients with severe mental illness visiting the Collaborative Centre for Cardiometabolic Health in Psychosis clinics and examine the effect of demographic, medical and social factors on Oral Health (OH). Methods The cross‐sectional study included adults aged 18–65 years with severe mental illness
Shilpi Ajwani +3 more
wiley +1 more source
Clozapine-induced insulin-resistant hyperglycemia in a diabetic patient
Indian Journal of Psychological Medicine, 2018 Clozapine is superior to all other antipsychotics in treatment-resistant schizophrenia. However, metabolic side effects are common while treating patients with clozapine.
Vijay Chathoth +2 more
doaj +1 more source
Clozapine use in personality disorder and intellectual disability [PDF]
, 2015 Purpose: Clozapine is a well-known antipsychotic medication licensed for treatment-resistant schizophrenia, but there is limited research available to suggest its efficacy in the context of personality disorder and intellectual disabilities presenting ...
Alexander, Regi Tharian +6 more
core +1 more source
Understanding excessive sleep in people with psychotic disorders
British Journal of Clinical Psychology, EarlyView.Abstract Background There has been increasing attention to sleep disturbances such as insomnia in psychosis, due to its impact on symptoms, well‐being, and recovery. However, excessive sleep and extended sleep duration are common in psychosis (partly linked to sedating antipsychotic medication) and have been relatively neglected, despite plausible ...
Kate Robbins +2 more
wiley +1 more source
Effect of adjunctive ranitidine for antipsychotic-induced weight gain: A systematic review of randomized placebo-controlled trials [PDF]
, 2017 This study was a meta-analysis of randomized controlled trials (RCTs) of ranitidine as an adjunct for antipsychotic-induced weight gain in patients with schizophrenia.
Chen, Rui +13 more
core +3 more sources
British Journal of Pharmacology, EarlyView.Abstract Background and Purpose Chemotherapy‐induced peripheral neuropathy (CIPN) is a prevalent and treatment‐resistant side effect of platinum‐based chemotherapy, characterised by mechanical allodynia. Cannabigerol (CBG), a non‐psychoactive cannabinoid, has shown antinociceptive potential, but its site and mechanism of action remain unclear.
Quinn W. Wade +7 more
wiley +1 more source
BJPsych OpenAims To review the practice of management of clozapine plasma levels in Solihull CMHTs between April and September 2023. Birmingham and Solihull Mental Health Foundation Trust (BSMHFT) clozapine guidelines were issued in January 2023 and further ...
Sarah O'Connor, Huma Hashmat
doaj +1 more source